HB1592 - TO PROVIDE PARITY IN HEALTH BENEFIT PLAN COVERAGE BETWEEN ORALLY ADMINISTERED ANTICANCER MEDICATION AND INTRAVENOUSLY ADMINISTERED ANTICANCER MEDICATION.
PDF
Bill Status History
Chamber
Date
Action
Vote
House
3/21/2017 2:31:16 PM
Notification that HB1592 is now Act 543
House
3/15/2017 9:00:18 AM
Correctly enrolled and ordered transmitted to the Governor's Office.
House
3/14/2017 4:40:00 PM
TO BE ENROLLED
House
3/14/2017 4:39:44 PM
Returned From the Senate as passed.
Senate
3/14/2017 3:42:59 PM
Returned to the House as passed.
Senate
3/9/2017 2:05:23 PM
Returned by the Committee, with the recommendation that it Do Pass
Senate
3/6/2017 6:14:16 PM
Read first time, rules suspended, read second time, referred to Senate Committee on Insurance and Commerce
Senate
3/6/2017 6:14:09 PM
Received from the House.
House
3/6/2017 2:19:21 PM
Read the third time and passed and ordered transmitted to the Senate.
House
3/2/2017 9:19:30 AM
REPORTED CORRECTLY ENGROSSED
House
3/2/2017 8:31:47 AM
Amendment No. 1 read and adopted and the bill ordered engrossed.
House
3/2/2017 8:31:05 AM
Placed on second reading for the purpose of amendment.
House
3/1/2017 10:19:53 AM
Returned by the Committee with the recommendation that it do pass as amended 1
House
2/21/2017 3:55:33 PM
Read the first time, rules suspended, read the second time and referred to the Committee on INSURANCE & COMMERCE- HOUSE
House
2/21/2017 8:59:00 AM
Filed
Amendments
Chamber
No.
Sponsor
Introduction Date
Document